Industry Overview - The biotechnology sector remains relevant due to the ongoing human desire to find solutions for diseases and conditions, despite its unpredictability and associated risks [1][2] - The global biotech market was valued at $1.55 trillion last year and is projected to grow at a compound annual growth rate of 13.96% from 2024 to 2030, potentially reaching $3.88 trillion [10] Company Analysis: Jazz Pharmaceuticals (JAZZ) - Jazz Pharmaceuticals has an average earnings per share (EPS) of $4.26 over the past four quarters, falling short of the anticipated $4.68, resulting in a negative earnings surprise of 9.75% [3] - Analysts project EPS could reach $20.72 on sales of $4.35 billion by fiscal 2025, compared to last year's EPS of $18.29 on revenue of $3.83 billion [4] - Current valuation metrics show JAZZ stock trading at 5.56X forward earnings and 1.97X trailing-year sales, down from 6.94X and 2.3X respectively from Q1 2023 to Q1 2024 [13] Company Analysis: Takeda Pharmaceutical (TAK) - Takeda Pharmaceutical's stock has underperformed, losing about 5% year-to-date and approximately 12% over the past 52 weeks, with a five-year return showing a 19% loss [5] - Analysts expect sales to rise 8.7% to $28.85 billion by the end of the year, indicating potential for recovery [6] - The current revenue multiple for TAK stock is 1.58X, slightly down from 1.68X the previous year, suggesting room for valuation improvement [16] Company Analysis: Pacira BioSciences (PCRX) - Pacira BioSciences has an average EPS of 75 cents over the past four quarters, narrowly missing the consensus estimate of 76 cents, leading to a negative earnings surprise of 1% [7] - Analysts forecast EPS could reach $3.64 on revenue of $760.61 million by fiscal 2025, up from last year's EPS of $2.81 on sales of $674.98 million [8] - The current valuation shows PCRX stock trading at a forward earnings multiple of 7.47X and a sales multiple of 1.57X, down from 10.03X and 2.47X respectively over the prior year [19]

This Earnings ESP, combined with its Zacks Rank #4 (Sell), makes it difficult to conclusively predict that Stevanato will beat the consensus EPS estimate. Over the last four quarters, the company surpassed EPS estimates just once. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Jazz doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. ...

Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing por ...

DUBLIN, July 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 second quarter financial results on Wednesday, July 31, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 second quarter financial results and provide a business and financial update. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceutica ...

Investors in JAZZ Pharmaceuticals plc (JAZZ) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $70.00 Call had some of the highest implied volatility of all equity options today. Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an ...

"I am delighted to be stepping into the role of CCO and look forward to leading the combined commercial organization as we continue to scale. I am deeply invested in Jazz's mission and purpose to help patients and remain focused on our commitment to deliver sustainable growth and enhanced value as an innovative global biopharmaceutical company," said Ms. Pearce. "I have had the privilege of leading Jazz's Europe and International organization since 2020 and look forward to continuing to partner closely with ...

Jazz Pharmaceuticals (JAZZ) announced that a mid-stage study evaluating the efficacy and safety of its investigational candidate, suvecaltamide (JZP385), in adult patients with essential tremor (ET) did not meet its primary endpoint. The study also failed to achieve statistical significance on the key secondary endpoint of the Clinical Global Impression-Severity scale, which is a measure of the severity of illness compared with placebo at week 12. Jazz's shares lost 4.7% during trading hours on Jun 20, afte ...

Jazz announced that suvecaltamide failed to meet the primary endpoint in the phase 2b trial, but the company is blaming the placebo response: The oxybate franchise is doing well despite the availability of generic Xyrem and the recent launch of Lumryz Jazz Pharmaceuticals earnings reports Jazz Pharmaceuticals earnings reports deliormanli Suvecaltamide fails in the phase 2b trial in patients with essential tremor While not statistically significant, numeric improvements were observed on the primary endpoint ...

Core Insights - Jazz Pharmaceuticals announced top-line results from the Phase 2b clinical trial evaluating suvecaltamide (JZP385) for essential tremor, which did not achieve statistical significance on the primary endpoint compared to placebo [6][11] - The trial involved 420 participants across four countries and assessed the efficacy and safety of suvecaltamide at doses of 10mg, 20mg, and 30mg [11] - Suvecaltamide was well tolerated, with a safety profile consistent with previous studies, and the most common treatment-emergent adverse events were mild to moderate [7] Phase 2b Trial Details - The trial was a 12-week, multicenter, double-blind, randomized, placebo-controlled study [11] - The primary endpoint was the modified TETRAS composite outcome score, while the key secondary endpoint measured the percentage of participants with a ≥1 point improvement on the CGI-S scale [11] - Numeric improvements were observed at the 30mg dose versus placebo, although not statistically significant [1][6] About Suvecaltamide - Suvecaltamide is a highly selective and state-dependent modulator of T-type calcium channels, which are involved in muscle movement control [3] - The ongoing Phase 2 proof-of-concept trial in Parkinson's disease tremor is expected to provide further insights, with results anticipated in the first quarter of 2025 [11] Company Overview - Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing life-changing medicines for serious diseases with limited therapeutic options [8] - The company has a diverse portfolio, including therapies for sleep disorders, epilepsy, and a growing range of cancer treatments [8]

"We are encouraged by the updated results from the pivotal HERIZON-BTC-01 trial demonstrating sustained clinical activity in previously treated patients with advanced HER2-positive BTC. Results from HERIZON- BTC-01 were included in the Biologics License Application (BLA) for zanidatamab, which was granted Priority Review by the FDA earlier this week, as well as in the Marketing Authorization Application for zanidatamab which was recently submitted to the European Medicines Agency," said Rob Iannone, M.D., M ...